Related Experiment Video
Updated: Jun 2, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Unmasking the apoptotic potential of DHODH inhibition through targeting adaptive mitophagy
Xiaowen Huang1,2, Zichang Guo2, Bowen Liu2,3
1School of Life Sciences, Fudan University, Shanghai, China.
Abstract:
Targeting dihydroorotate dehydrogenase (DHODH) to restrict de novo pyrimidine synthesis is a promising anticancer strategy. However, the efficacy of DHODH inhibitors, such as brequinar (BQR), is often constrained by modest single-agent cytotoxicity, necessitating the exploration of combination therapies. Here, using mt-Keima-based mitophagy reporters and CRISPR/Cas9-mediated gene knockout models, we reveal a critical adaptive mechanism whereby BQR-induced mitochondrial reactive oxygen species (mtROS) trigger protective mitophagy. Crucially, we demonstrate that inhibiting this autophagy process synergistically enhances BQR's anti-tumor activity both in vitro and in vivo. This combination leads to enhanced mtROS accumulation and severe lipid peroxidation, ultimately triggering caspase-dependent apoptosis, while ferroptosis does not appear to be the dominant mechanism under these conditions. Our findings identify mitophagy as a key mechanism of resistance to DHODH inhibition and provide a strong rationale for a combinatorial strategy to enhance the therapeutic efficacy of this class of drugs.
Insights
Dihydroorotate dehydrogenase (DHODH) inhibitors show promise in cancer therapy. Combining DHODH inhibitors with mitophagy inhibitors enhances anti-tumor activity by increasing mitochondrial damage and apoptosis.
Area of Science:
- Cancer Biology
- Molecular Oncology
- Drug Discovery
Background:
- Targeting de novo pyrimidine synthesis via dihydroorotate dehydrogenase (DHODH) is a key anticancer strategy.
- DHODH inhibitors like brequinar (BQR) have limited single-agent efficacy due to adaptive resistance mechanisms.
Purpose of the Study:
- To investigate the adaptive mechanisms limiting DHODH inhibitor efficacy.
- To explore combination therapies to overcome resistance to DHODH inhibitors.
Main Methods:
- Utilized mt-Keima-based mitophagy reporters to monitor mitophagy.
- Employed CRISPR/Cas9 gene knockout models to study resistance mechanisms.
- Assessed synergistic effects of combining DHODH and mitophagy inhibitors in vitro and in vivo.
Main Results:
- Brequinar (BQR) treatment induces mitochondrial reactive oxygen species (mtROS), triggering protective mitophagy.
- Inhibiting mitophagy synergistically enhances BQR's anti-tumor activity.
- The combination therapy leads to increased mtROS, lipid peroxidation, and caspase-dependent apoptosis.
Conclusions:
- Mitophagy acts as a crucial adaptive resistance mechanism against DHODH inhibitors.
- Combining DHODH inhibitors with mitophagy inhibitors represents a promising strategy to enhance anti-cancer efficacy.
- This approach warrants further investigation for clinical translation in cancer treatment.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
07:56Visualizing Mitophagy with Fluorescent Dyes for Mitochondria and Lysosome
Published on: November 30, 2022
Related Concept Videos
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Apoptosis
Cellular Injury V: Apoptosis and Autophagy